

A 839977

Catalog No: tcsc1691



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

870061-27-1

Formula:

$C_{19}H_{14}Cl_2N_6O$

Pathway:

Membrane Transporter/Ion Channel

Target:

P2X Receptor

Purity / Grade:

>98%

Solubility:

H₂O :

Observed Molecular Weight:

413.26

Product Description


A-839977 is a novel and selective P2X7 antagonist; blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC₅₀ values are 20, 42 and 150 nM respectively).

IC₅₀ Value:

Target: P2X7

in vitro: A-839977 potently ($IC_{50}=20-150$ nM) blocked BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors. A-839977 also potently blocked agonist-evoked YO-PRO uptake and IL-1beta release from differentiated human THP-1 cells [1].

in vivo: Systemic administration of A-839977 dose-dependently reduced thermal hyperalgesia produced by intraplantar administration of complete Freund's adjuvant (CFA) ($ED_{50}=100$ micromol/kg, i.p.) in rats. A-839977 also produced robust antihyperalgesia in the CFA model of inflammatory pain in wild-type mice ($ED_{50}=40$ micromol/kg, i.p.), but the antihyperalgesic effects of A-839977 were completely absent in IL-1alpha knockout mice [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!